Novamind Inc. (OTCQB: NVMDF), a mental health company specializing in psychedelic medicine, has announced the launch of a new clinic located in downtown Salt Lake City specializing in integrative behavioral health and services for adults with substance use disorders.
Novamind Partners With Bienstar Wellness, Opening Door To Ibogaine Treatment For Addiction Disorders
December 2, 2:30 PM
Novamind Inc. (OTCQB: NVMDF) a mental health company specializing in psychedelic medicine, recently announced a strategic investment and advisory agreement with Bienstar Wellness Corp, an Uruguay-based mental health company, to assist in the expansion of Latin Ameri
Psychedelic Companies Keenly Aware Of Creating Therapies As Healthcare Reimbursement Possibility Looms
November 22, 3:20 PM
In the quest to design effective and affordable psychedelic treatments for a range of maladies that include PTSD and depression, one key thought on the minds of company executives and clinicians alike seems to be how to motivate healthcare insurance companies to cover the cost of psychedelic therapies.
November 18, 11:38 AM
Four major health insurance providers recently approved psychedelic medicine company Novamind Inc. (CSE: NM) (OTCQB: NVMDF) for direct billing of intravenous (IV) ketamine for treatment-resistant depression (TRD).
Psychedelic Medicine For End-Of-Life And Palliative Care Patients: Novamind Launches Treatment Program
October 7, 4:48 PM
Novamind (Canadian: NM) (OTCQB: NVMDF), a company in the psychedelics space that operates several mental health clinics in Utah, announced a new program for palliative care patients experiencing chronic and serious illnesses.
September 13, 12:46 PM
By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate leaders, working to create new methods for the treatment of mental health and other serious conditions.